Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Moderate Buy” by Analysts
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eighteen have issued a buy recommendation and one […]
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eighteen have issued a buy recommendation and one […]
